期刊文献+

FGFR3真核表达载体的构建及其在人白血病细胞系K562中的表达

Construction of eukaryotic expression vectors of FGFR3 gene and their expressions in human leukemia K562 cell line
下载PDF
导出
摘要 目的:构建成纤维细胞生长因子受体3(FGFR3)真核表达载体MSCV/puro-fgfr3-WT和MSCV/purofgfr3-DN,并检测FGFR3蛋白在人白血病细胞系K562中的表达。方法:通过PCR法获得FGFR3全长基因(fgfr3-WT)和截短失活型的FGFR3(fgfr3-DN),经双酶切后与真核表达载体MSCV/puro连接,构建MSCV/puro-fgfr3-WT和MSCV/puro-fgfr3-DN重组表达质粒。经PCR、双酶切及测序鉴定正确后,脂质体介导转染至人白血病细胞系K562中,经puromycin抗性筛选后,Western blotting法和流式细胞术检测细胞中FGFR3蛋白的表达。结果:PCR法鉴定MSCV/puro-fgfr3-WT和MSCV/puro-fgfr3-DN重组质粒,2个质粒分别扩增出2 400bp的fgfr3-WT全长基因片段和1 200bp的fgfr3-DN截短型片段,表明成功扩增fgfr3-WT全长基因和1 200bp的fgfr3-DN基因;双酶切MSCV/puro-fgfr3-WT重组质粒,获得2 400bp的目的基因片段;测序显示,fgfr3-WT片段大小为2 400bp,Blast对比分析表明测序结果与GenBank中的FGFR3序列完全一致。fgfr3-DN片段大小与预先设计的序列完全一致,表明成功构建野生型FGFR3和突变失活型FGFR3真核表达载体;Western blotting检测,与对照组(K562-MSCV)比较,MSCV/puro-fgfr3-WT转染组(K562-WT)FGFR3蛋白表达水平增加,表达水平是对照组的10倍以上;MSCV/puro-fgfr3-DN转染组(K562-DN)的截短型的FGFR3(K562-DN)高表达,而对照组和K562-WT转染组则无此片段;流式细胞术检测,K562-WT组有57.5%的细胞高表达FGFR3,K562-DN组有41.5%的细胞高表达FGFR3-DN。结论:成功构建高表达野生型和突变型FGFR3的人白血病细胞系K562。 Objective To construct the eukaryotic expression vectors of fibroblast growth factor receptor 3(FGFR3) MSCV/puro-fgfr3-WT and MSCV/puro-fgfr3-DN, and to detect their expressions in human chronic myeloid leukemia(CML)K562 cell line.Methods The full-length FGFR3 (fgfr3-WT)and dominant negative FGFR3 (fgfr3-DN)were amplified by polymerase chain reaction (PCR). The two genes were respectively digested with EcoRⅠand BamHⅠ,and then ligated into MSCV/puro to construct the recombinant plasmids MSCV/puro-fgfr3-WT and MSCV/puro-fgfr3-DN which were tranduced into K562 cells by LipofectaminTM 2000 after PCR,double digestion and DNA sequencing.The expressions of FGFR3 protein in K562 cells were detected by Western blotting and flow cytometry. Results The recombinant plasmids MSCV/puro-fgfr3-WT and MSCV/puro-fgfr3-DN were amplified by PCR method, and the results showed fgfr3-WT of 2 400 bp and fgfr3-DN of 1 200 bp had been successfully cloned into MSCV-puro vector. The 2 400 bp fragment was oblained after double digestion of recombinant plasmid.The sequencing results showed that the size of fgfr3-WT was 2 400 bp which was the same as the sequence from GeneBank.Fgfr3-DN of 1 200 bp was also in conformity with the expected sequence.Compared with control (K562 MSCV)group,the expression level of FGFR3-WT in MSCV/puro-fgfr3-WT transfection (K562-WT)group was increased to above 10 times.There was high expression of FGFR3-DN in MSCV/puro-FGFR3-DN transfection (K562-DN)group,but there was no expressions in control(K562 MSCV)group and K562-WT group.The flow cytometry results showed that the high expressions of FGFR3-WT were in 57.5% cells in K562-DN group and the high expressions of FGFR3-DN were in 41.5% cells in K562-DN group. Conclusion The K562 cell lines highly expressing FGFR3-WT and FGFR3-DN are constructed successfully.
出处 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2014年第3期465-470,共6页 Journal of Jilin University:Medicine Edition
基金 国家自然科学基金资助课题(81370640) 吉林省科技厅重点科技攻关项目资助课题(20130206003YY) 吉林省科技厅医药产业发展专项资金资助课题(20130727041YY)
关键词 受体 成纤维细胞生长因子 3型 真核表达载体 K562 细胞系 基因转染 白血病 粒-单核细胞 慢性 receptor, fibroblast growth factor, type 3 eukaryotic expression vector K562 cell line gene transfectiom leukemia, myelomonocytic, chronic
  • 相关文献

参考文献20

  • 1O’Dwyer ME,Druker BJ.The role of the tyrosine kinase inhibitor STI571in the treatment of cancer[J].Curr Cancer Drug Targets,2001,1(1):49-57.
  • 2Packer LM,Rana S,Hayward R,et al.Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia[J].Cancer Cell,2011,20(6):715-727.
  • 3Plowright EE,Li Z,Bergsagel PL,et al.Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis[J].Blood,2000,95(3):992-998.
  • 4Al-Ahmadie HA,Iyer G,Janakiraman M,et al.Somatic mutation of fibroblast growth factor receptor-3(FGFR3)defines a distinct morphological subtype of high-grade urothelial carcinoma[J].J Pathol,2011,224(2):270-279.
  • 5Pandith AA,Shah ZA,Siddiqi MA.Oncogenic role of fibroblast growth factor receptor 3in tumorigenesis of urinary bladder cancer[J].Urol Oncol,2013,31(4):398-406.
  • 6Henson BJ,Gollin SM.Overexpression of KLF13 and FGFR3in oral cancer cells[J].Cytogenet Genome Res,2010,128(4):192-198.
  • 7Goriely A,Hansen RM,Taylor IB,et al.Activating mutations in FGFR3and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors[J].Nat Genet,2009,41(11):1247-1252.
  • 8Sonvilla G,Allerstorfer S,Heinzle C,et al.Fibroblast growth factor receptor 3-Ⅲc mediates colorectal cancer growth and migration[J].Br J Cancer,2010,102(7):1145-1156.
  • 9Dvorak P,Dvorakova D,Doubek M,et al.Increased expression of fibroblast growth factor receptor 3in CD34+BCR-ABL+cells from patients with chronic myeloid[J].Leukemia,2003,17(12):2418-2425.
  • 10Branford S,Rudzki Z,Walsh S,et al.Detection of BCRABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance,and mutations in the ATP phosphate-binding loop(P-loop)are associated with a poor prognosis[J].Blood,2003,102(1):276-283.

二级参考文献30

  • 1鲍立,江滨,黄晓军,王德炳,邱镜滢,卢锡京,陈欢,陆道培.Ph阳性急性淋巴细胞白血病的临床研究[J].中华血液学杂志,2005,26(1):31-34. 被引量:5
  • 2邱镜滢,朱伟,张艳,陈珊珊,江滨,史惠琳,师岩,何琦,党辉,王德炳,陆道培.Ph染色体阳性急性白血病细胞遗传学及临床研究[J].中国实验血液学杂志,2005,13(3):358-363. 被引量:12
  • 3ANDERSON LD, SAVARY CA, MULLEN CA. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease [J]. Blood, 2000, 95 (7):2426- 2433.
  • 4CHEN G, ZHANG WG, CAO XM, et al. Serological identification of immunogenic antigens in acute monocytic leukemia [J].Leukemia Res, 2005, 29(5):503-509.
  • 5ZHANG PY, ZHANG WG, HE AL, et al. Identification and functional characterization of the novel acute monocytic leukemia associated antigen MLAA-34 [J]. Cancer Immunol Immun, 2009, 58(2) :281-290.
  • 6KESSLER JH, MELIEF CJM. Identification of T-cell epitopcs for cancer immunotherapy [J]. Leukemia, 2007, 21(9): 1859- 1874.
  • 7HARNDAHL M, JUSTESEN S, LAMBERTH K, et al. Peptide binding to HLA class I molecuies: homogenous, high- throughput screening, and affinity assays [J]. J Biomol Screen, 2009, 14(2) :173-180.
  • 8BLATTMAN JN, GREENBERG PD. Cancer immunothcrapy: a treatment for the masses [J]. Science, 2004, 305(5681) :200- 205.
  • 9JAGER E, JAGER D, KNUTH A. Antigen-specific immunotherapy and cancer vaccines [J]. Int J Canccr, 2003, 1(16(6): 817-820.
  • 10VAN DER BRUGGEN P, ZHANG Y, CHAUX P, ct al. Tumorspecific shared antigenic peptides rccognized by human T cclls [J]. Immunol Rev, 2002, 188(1) :51-64.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部